PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

daptomycin Side Effects

The reactions most often reported to the FDA for daptomycin (also sold as Cubicin), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

8,426
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2004 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of daptomycin come from 8,426 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 8,426 reports to the FDA Adverse Event Reporting System (FAERS) for daptomycin (Cubicin): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

8,426

Reports Mentioning Death

1,184

14.1% of reports — not proof the medicine caused the death

Hospitalizations

4,822

57.2% of reports

Top Indication

Product Used For Unknown Indication

Most Reported Adverse Reactions

ACUTE KIDNEY INJURY
527
PYREXIA
459
EOSINOPHILIC PNEUMONIA
418
RHABDOMYOLYSIS
336
EOSINOPHILIA
328
BLOOD CREATINE PHOSPHOKINASE INCREASED
327
DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS
322
NEUTROPENIA
270
RASH
255
THROMBOCYTOPENIA
250
INTERSTITIAL LUNG DISEASE
231
PNEUMONITIS
224
DRUG INTERACTION
217
DYSPNOEA
214
CHILLS
207
SEPSIS
206
PNEUMONIA
203

Who Reports Side Effects

Gender Distribution

Female 3,076 (39%)
Male 4,784 (61%)
Unknown 5

Age Distribution

0-17 263 (4%)
18-44 1,100 (15%)
45-64 2,369 (33%)
65-74 1,939 (27%)
75+ 1,611 (22%)

Reporting Trend by Year

2004 2025

Reactions in Death Reports

Top reactions reported in 1,184 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
DEATH 160
MULTIPLE ORGAN DYSFUNCTION SYNDROME 127
SEPSIS 114
SEPTIC SHOCK 105
ACUTE KIDNEY INJURY 68
PNEUMONIA 63
THROMBOCYTOPENIA 57
EOSINOPHILIC PNEUMONIA 48
NEUTROPENIA 44
RESPIRATORY FAILURE 44
ENTEROCOCCAL INFECTION 42
DYSPNOEA 41
CARDIAC ARREST 40
STAPHYLOCOCCAL INFECTION 37
TREATMENT FAILURE 37
HYPOTENSION 36
PYREXIA 36
CONDITION AGGRAVATED 33

Reactions in Hospitalization Reports

Top reactions in 4,822 reports where hospitalization was an outcome.

Reaction Reports
ACUTE KIDNEY INJURY 395
PYREXIA 303
EOSINOPHILIC PNEUMONIA 284
EOSINOPHILIA 252
RHABDOMYOLYSIS 244
DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS 215
THROMBOCYTOPENIA 179
INTERSTITIAL LUNG DISEASE 172
AGRANULOCYTOSIS 155
NEUTROPENIA 153
BLOOD CREATINE PHOSPHOKINASE INCREASED 149
RASH 143
SEPSIS 140
DRUG INTERACTION 135
HEPATIC CYTOLYSIS 135
PNEUMONIA 131
DYSPNOEA 124
PNEUMONITIS 124

Compare daptomycin vs amikacin →

What the FAERS Data Reveals About daptomycin Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 8,426 voluntary reports linked to daptomycin and its brand equivalents (Cubicin), spanning 2004 through 2025. Of those, 1,184 (14.1%) listed death as an outcome and 4,822 (57.2%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 39% were female and 61% male; age distribution skews toward 45-64, with 2,369 reports in that bracket. The single most reported reaction is acute kidney injury with 527 submissions, followed by pyrexia and eosinophilic pneumonia.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.